Pulse Biosciences Inc SEC Filings

Form 144 filed for Pulse Biosciences, Inc. (PLSE) reports a proposed sale of 25,000 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $406,750.00. The filing states the shares were acquired and paid for on 09/18/2025 by exercise of stock options from the issuer, and the approximate date of sale is also listed as 09/18/2025.

The filing lists 67,278,347 shares outstanding, and no other sales by the reporting person in the past three months were reported. The filer represents there is no undisclosed material adverse information and includes the standard signed certification language on trading plans and criminal penalties for false statements.

PULSE BIOSCIENCES insider transactions: Darrin Uecker, Chief Technology Officer and director, executed option exercises and sales under a Rule 10b5-1 plan adopted June 12, 2025. On 09/11/2025, 09/12/2025 and 09/15/2025 he exercised three separate $4 stock option tranches of 25,000 shares each and contemporaneously sold 25,000 shares on each date. The reported weighted-average sale prices ranged by date: $14.41–$15.14 (09/11 weighted $14.78), $13.80–$14.76 (09/12 weighted $14.32), and $15.18–$17.20 (09/15 weighted $15.77). Following the transactions the filings show beneficial ownership positions reported in the Form 4 tables (e.g., 122,872 shares on the non-derivative table after sales). The options became fully vested on September 8, 2019 per the employment agreement.

Pulse Biosciences (PLSE) reported a Form 144 notice showing a proposed sale of 120,000 common shares by means of a broker, with an aggregate market value of $1,772,400 and an approximate sale date of 09/11/2025 on NASDAQ. The filing states the shares were acquired and paid for on 09/11/2025 through the exercise of stock options issued by the company, with payment made in cash. The broker listed is Morgan Stanley Smith Barney LLC. The filer also disclosed two prior open-market sales by the same person in June 2025 totaling 30,000 shares for gross proceeds of $485,700. The notice includes the standard representation that the seller is unaware of any undisclosed material adverse information.

Pulse Biosciences announced FDA approval of an Investigational Device Exemption (IDE) to begin a clinical study of its nsPFA Cardiac Surgical System for treating atrial fibrillation (AF). The approved NANOCLAMP AF study is a single-arm, prospective trial designed to show primary effectiveness when used in concomitant cardiac surgery. Up to 20 sites (including two outside the U.S.) are planned to enroll as many as 136 patients. The filing attaches a company press release and reiterates standard forward-looking statement cautions about clinical, regulatory, and technological risks.

Pulse Biosciences announced the enrollment of the first patients in a multicenter, IRB-approved study (PRECISE) evaluating its nsPFA™ Percutaneous Electrode System to treat benign thyroid nodules (BTNs). The filing states the press release dated September 2, 2025, confirms successful initial procedures and that the release is attached as Exhibit 99.1.

The company describes the study as multicenter and IRB-approved, indicating clinical development progress for its proprietary nsPFA technology in a new indication. No financial results, timelines for completion, patient numbers beyond “first patients,” or efficacy/safety data are included in the filing.

Pulse Biosciences announced publication of early clinical data from a first-in-human, single-arm feasibility study of its CellFX nsPFA Percutaneous Electrode System to treat benign thyroid nodules. The study, conducted at a single center in Naples, Italy, used ultrasound-guided ablation for tissue-response assessments and therapeutic intent. Follow-up ultrasounds showed no intranodular fibrosis or scarring. Fully treated nodules had an average 86% reduction in size at one year, with individual reductions up to 93%, and patients experienced symptom relief with reductions greater than 48% as early as two weeks. The company attached the related press release as an exhibit.

Richard van den Broek, a director of Pulse Biosciences, was granted a stock option on 08/15/2025 to purchase 30,000 shares of common stock at an exercise price of $16.16 per share. The option becomes exercisable beginning 08/15/2025 and expires 08/15/2035. The shares subject to the option vest in equal monthly installments over one year, with the first installment on 09/15/2025, contingent on continued service.

Mahkam Zanganeh, a director of Pulse Biosciences (PLSE), reported receipt of two stock option grants on 08/15/2025 totaling 54,134 options. Both options have an exercise price of $16.16 and expire on 08/15/2035. The first option covers 30,000 shares and vests in equal monthly installments over one year beginning 09/15/2025. The second covers 24,134 shares and vests in equal quarterly installments over one year beginning 09/05/2025. Ownership after the transactions is reported as 30,000 and 24,134 shares respectively, held directly.

Pulse Biosciences director and 10% owner Robert W. Duggan received two stock option grants on 08/15/2025 totaling 50,792 options to buy common stock at an exercise price of $16.16 per share. One option for 30,000 shares vests monthly over one year beginning 09/15/2025. The second option for 20,792 shares vests quarterly over one year beginning 09/05/2025. Both options expire 08/15/2035. The Form 4 was filed as a single reporting person filing and signed by an attorney-in-fact on 08/19/2025.